Characterization of the novel DNA gyrase inhibitor AZD0914: Low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1478-1486

  Alm, Richard A ^a   Lahiri, Sushmita D ^a   Kutschke, Amy ^a   Otterson, Linda G ^a   McLaughlin, Robert E ^a   Whiteaker, James D ^a   Lewis, Lisa A ^b   Su, Xiaohong ^c   Huband, Michael D ^a   Gardner, Humphrey ^a   Mueller, John P ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c INSTITUTE OF DERMATOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 0914; AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE IV; GYRASE INHIBITOR; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TETRACYCLINE; UNCLASSIFIED DRUG; BARBITURIC ACID DERIVATIVE; SPIRO COMPOUND; ZOLIFLODACIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CROSS RESISTANCE; CRYSTAL STRUCTURE; DIFFERENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; GENE SEQUENCE; GONORRHEA; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; CHEMISTRY; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

BARBITURATES; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; NEISSERIA GONORRHOEAE; SPIRO COMPOUNDS; TOPOISOMERASE II INHIBITORS;

EID: 84923240925     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04456-14     Document Type: Article

References (33)

1. World Health Organization. 2012. WHO: urgent action needed to prevent the spread of untreatable gonorrhoea. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/news/notes/2012/gonorrhoea-20120606/en/.
2. Unemo M, Golparian D, Shafer WM. 2014. Challenges with gonorrhea in the era of multi-drug and extensively drug resistance-are we on the right track? Expert Rev Anti Infect Ther 12:653-656. http://dx.doi.org/10.1586/14787210.2014.906902.
3. Bala M, Kakran M, Singh V, Sood S, Ramesh V, Members of WHO GASP SEAR Network. 2013. Monitoring antimicrobial resistance in Neisseria gonorrhoeae in selected countries of the WHO South-East Asia Region between 2009 and 2012: a retrospective analysis. Sex Transm Infect 89(Suppl 4):iv28-iv35. http://dx.doi.org/10.1136/sextrans-2012-050904.
4. Dillon JA, Trecker MA, Thakur SD, Gonococcal Antimicrobial Surveillance Program Network in Latin America and Caribbean 1990-2011. 2013. Two decades of the gonococcal antimicrobial surveillance program in South America and the Caribbean: challenges and opportunities. Sex Transm Infect 89(Suppl 4):iv36-iv41. http://dx.doi.org/10.1136/sextrans-2012-050905.
5. Endimiani A, Guilarte YN, Tinguely R, Hirzberger L, Selvini S, Lupo A, Hauser C, Furrer H. 2014. Characterization of Neisseria gonorrhoeae isolates detected in Switzerland (1998-2012): emergence of multidrugresistant clones less susceptible to cephalosporins. BMC Infect Dis 14:106. http://dx.doi.org/10.1186/1471-2334-14-106.
6. Kubanova A, Kubanov A, Frigo N, Solomka V, Semina V, Vorobyev D, Khairullin R, Unemo M. 2014. Russian gonococcal antimicrobial susceptibility programme (RU-GASP)-resistance in Neisseria gonorrhoeae during 2009-2012 and NG-MAST genotypes in 2011 and 2012. BMC Infect Dis 14:342. http://dx.doi.org/10.1186/1471-2334-14-342.
7. Martin I, Sawatzky P, Liu G, Allen V, Lefebvre B, Hoang L, Lovgren M, Haldane D, Caeseele PV, Horsman G, Garceau R, Ratnam S, Wong T, Gilmour M. 2013. Antimicrobial susceptibilities and distribution of sequence types of Neisseria gonorrhoeae isolates in Canada: 2010. Can J Microbiol 59:671-678. http://dx.doi.org/10.1139/cjm-2013-0357.
8. Mlynarczyk-Bonikowska B, Serwin AB, Golparian D, Walter de Walthoffen S, Majewski S, Koper M, Malejczyk M, Domeika M, Unemo M. 2014. Antimicrobial susceptibility/resistance and genetic characteristics of Neisseria gonorrhoeae isolates from Poland, 2010-2012.BMCInfect Dis 14:65. http://dx.doi.org/10.1186/1471-2334-14-65.
9. Zhu BY, Yu RX, Yin Y, Chen X, Li W, Dai XQ, Liang M, Gan Q, Huang YJ, Wei JP. 2014. Surveillance of antimicrobial susceptibilities of Neisseria gonorrhoeae in Nanning, China, 2000 to 2012. Sex Transm Dis 41:501-506. http://dx.doi.org/10.1097/OLQ.0000000000000157.
10. Vandepitte J, Hughes P, Matovu G, Bukenya J, Grosskurth H, Lewis DA. 2014. High prevalence of ciprofloxacin-resistant gonorrhea among female sex workers in Kampala, Uganda (2008-2009). Sex Transm Dis 41:233-237. http://dx.doi.org/10.1097/OLQ.0000000000000099.
11. Kirkcaldy RD, Kidd S, Weinstock HS, Papp JR, Bolan GA. 2013. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sex Transm Infect 89(Suppl 4):iv5-iv10. http://dx.doi.org/10.1136/sextrans-2013-051162.
12. Belland RJ, Morrison SG, Ison C, Huang WM. 1994. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol 14:371-380. http://dx.doi.org/10.1111/j.1365-2958.1994.tb01297.x.
13. Deguchi TM, Yasuda M, Nakano M, Ozeki S, Ezaki T, Saito I, Kawada Y. 1996. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother 40:1020-1023.
14. Alcala B, Arreaza L, Salcedo C, Antolin I, Borrell N, Cacho J, De Las Cuevas C, Otero L, Sauca G, Vazquez F, Villar H, Vazquez JA. 2003. Molecular characterization of ciprofloxacin resistance of gonococcal strains in Spain. Sex Transm Dis 30:395-398. http://dx.doi.org/10.1097/00007435-200305000-00004.
15. Deguchi TM, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Kawada Y, Ezaki T, Saito I. 1996. Uncommon occurrence of mutations in the gyrB gene associated with quinolone resistance in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 40:2437-2438.
16. Jacobsson S, Golparian D, Alm RA, Huband M, Mueller J, Jensen JS, Ohnishi M, Unemo M. 2014. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrugresistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 58:5585-5588. http://dx.doi.org/10.1128/AAC.03090-14.
17. Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C. 2012. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 67:1858-1860. http://dx.doi.org/10.1093/jac/dks162.
18. Shimuta K, Unemo M, Nakayama S, Morita-Ishihara T, Dorin M, Kawahata T, Ohnishi M, Antibiotic-Resistant Gonorrhea Study Group. 2013. Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance. Antimicrob Agents Chemother 57:5225-5232. http://dx.doi.org/10.1128/AAC.01295-13.
19. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55:3538-3545. http://dx.doi.org/10.1128/AAC.00325-11.
20. Palmer T, Walkup G, Basarab G, Fan J, Mills SD, Shapiro AB, Sriram S, Andrews B, Gao N, Thresher J, deJonge B, Kern G. 2014. AZD0914, a topoisomerase inhibitor with novelMOIfor treatment of infections with Neisseria gonorrhoeae, poster C-1422. 54th Annu Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC.
21. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Ruiz J, Jurado A, Garcia-Mendez E, Marco F, Aguilar L, Jimenez de Anta MT, Vila J. 2001. Frequency of selection of fluoroquinoloneresistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. J Antimicrob Chemother 48:545-548. http://dx.doi.org/10.1093/jac/48.4.545.
24. Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35:1647-1650. http://dx.doi.org/10.1128/AAC.35.8.1647.
25. Miller AA, Bundy GL, Mott JE, Skepner JE, Boyle TP, Harris DW, Hromockyj AE, Marotti KR, Zurenko GE, Munzner JB, Sweeney MT, Bammert GF, Hamel JC, Ford CW, Zhong WZ, Graber DR, Martin GE, Han F, Dolak LA, Seest EP, Ruble JC, Kamilar GM, Palmer JR, Banitt LS, Hurd AR, Barbachyn MR. 2008. Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob Agents Chemother 52:2806-2812. http://dx.doi.org/10.1128/AAC.00247-08.
26. West KL, Meczes EL, Thorn R, Turnbull RM, Marshall R, Austin CA. 2000. Mutagenesis of E477 or K505 in the B= domain of human topoisomerase II beta increases the requirement for magnesium ions during strand passage. Biochemistry 39:1223-1233. http://dx.doi.org/10.1021/bi991328b.
27. Huband MD, Bradford P, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF, Mueller JP. 2014. In vitro antibacterial activity of AZD0914: a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria. Antimicrob Agents Chemother 59:467-474. http://dx.doi.org/10.1128/AAC.04124-14.
28. Aravind L, Leipe DD, Koonin EV. 1998. Toprim-a conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases,OLDfamily nucleases and RecR proteins. Nucleic Acids Res 26:4205-4213. http://dx.doi.org/10.1093/nar/26.18.4205.
29. Laponogov I, Pan XS, Veselkov DA, McAuley KE, Fisher LM, Sanderson MR. 2010. Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS One 5:e11338. http://dx.doi.org/10.1371/journal.pone.0011338.
30. Pan XS, Gould KA, Fisher LM. 2009. Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob Agents Chemother 53:3822-3831. http://dx.doi.org/10.1128/AAC.00113-09.
31. Huband MD, Cohen MA, Zurack M, Hanna DL, Skerlos LA, Sulavik MC, Gibson GW, Gage JW, Ellsworth E, Stier MA, Gracheck SJ. 2007. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant Gram-positive and fastidious organism groups. Antimicrob Agents Chemother 51:1191-1201. http://dx.doi.org/10.1128/AAC.01321-06.
32. Aldred KJ, McPherson SA, Turnbough CL, Jr, Kerns RJ, Osheroff N. 2013. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res 41:4628-4639. http://dx.doi.org/10.1093/nar/gkt124.
33. Aldred KJ, Schwanz HA, Li G, McPherson SA, Turnbough CL, Jr, Kerns RJ, Osheroff N. 2013. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. ACS Chem Biol 8:2660-2668. http://dx.doi.org/10.1021/cb400592n.